Claims for Patent: 8,163,287

Summary for Patent: 8,163,287

Title:	Combination therapy of her expressing tumors
Abstract:	The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
Inventor(s):	Sliwkowski; Mark X. (San Carlos, CA), Kelsey; Stephen M. (Montara, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	11/490,438
Patent Claims:	1. A method for the treatment of lung tumor comprising administering to a human subject with a lung tumor expressing EGFR and HER2, an effective amount of a HER2 antibody which is a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's tumor does not show a complete response to treatment with said HER2 antibody or said EGFR inhibitor when administered as a single agent, and is refractory to chemotherapy and/or radiation therapy. 2. The method of claim 1 wherein said tumor shows a partial response to treatment with said EGFR inhibitor administered as a single agent. 3. The method of claim 1 wherein said tumor shows a partial response to treatment with said HER2 antibody administered as a single agent. 4. The method of claim 1 wherein said tumor additionally expresses HER3. 5. The method of claim 1 wherein said tumor displays HER2 receptor overexpression or amplification. 6. The method of claim 1 wherein said tumor does not display HER2 receptor overexpression or amplification. 7. The method of claim 1 wherein said treatment increases the time to tumor progression and/or the time to death relative to treatment with said HER2 antibody or said EGFR inhibitor when administered as a single agent. 8. The method of claim 1 wherein said lung cancer is selected from the group consisting of small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, and squamous carcinoma of the lung. 9. The method of claim 8 wherein said lung cancer is non-small cell lung cancer (NSCLC). 10. The method of claim 9 wherein said treatment is provided as a second or third line therapy. 11. The method of claim 1 wherein said HER2 antibody binds to domain II of HER2 extracellular domain. 12. The method of claim 1 wherein said HER2 antibody binds to a junction between domains I, II and III of HER2 extracellular domain. 13. The method of claim 1 wherein said HER2 antibody is a humanized 2C4 antibody. 14. The method of claim 13 wherein said HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 11 and 12, respectively. 15. The method of claim 14 wherein said HER2 antibody is rhuMAb 2C4 (pertuzumab). 16. The method of claim 1 wherein said EGFR inhibitor is a non-peptide small molecule. 17. The method of claim 16 wherein said EGFR inhibitor has formula I: ##STR00013## wherein: X is halo or hydroxy; m is 1, 2, or 3; each R.sup.1 is independently selected from the group consisting of hydrogen, halo, hydroxy, hydroxyamino, carboxy, nitro, guanidino, ureido, cyano, trifluoromethyl, and --(C.sub.1-C.sub.4 alkylene)-W-(phenyl) wherein W is a single bond, O, S or NH; or each R.sup.1 is independently selected from R.sup.9 and C.sub.1-C.sub.4 alkyl substituted by cyano, wherein R.sup.9 is selected from the group consisting of R.sup.5, --OR.sup.6, --NR.sup.6R.sup.6, --C(O)R.sup.7, --NHOR.sup.5, --OC(O)R.sup.6, cyano, A and --YR.sup.5; R.sup.5 is C.sub.1-C.sub.4 alkyl; R.sup.6 is independently hydrogen or R.sup.5; R.sup.7 is R.sup.5, --OR.sup.6 or --NR.sup.6R.sup.6; A is selected from piperidino, morpholino, pyrrolidino, 4-R.sup.6-piperazin-1-yl, imidazol-1-yl, 4-pyridon-1-yl, --(C.sub.1-C.sub.4 alkylene)(CO2H), phenoxy, phenyl, phenylsulfanyl, C.sub.2-C.sub.4 alkenyl, and --(C.sub.1-C.sub.4 alkylene)C(O)NR.sup.6R.sup.6; and Y is S, SO, or SO.sub.2; wherein the alkyl moieties in R.sup.5, --OR.sup.6 and --NR.sup.6R.sup.6 are optionally substituted by one to three halo substituents and the alkyl moieties in R.sup.5, --OR.sup.6 and --NR.sup.6R.sup.6 are optionally substituted by 1 or 2 R.sup.9 groups, and wherein the alkyl moieties of said optional substituents are optionally substituted by halo or R.sup.9, with the proviso that two heteroatoms are not attached to the same carbon atom; or each R.sup.1 is independently selected from --NHSO.sub.2R.sup.5, phthalimido-(C.sub.1-C.sub.4)-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R.sup.10--(C.sub.2-C.sub.4)-alkanoylamino wherein R.sup.10 is selected from halo, --OR.sup.6, C.sub.2-C.sub.4 alkanoyloxy, --C(O)R.sup.7, and --NR.sup.6R.sup.6; and wherein said --NHSO.sub.2R.sup.5, phthalimido-(C.sub.1-C.sub.4-alkylsulfonylamino, benzamido, benzenesulfonylamino, 3-phenylureido, 2-oxopyrrolidin-1-yl, 2,5-dioxopyrrolidin-1-yl, and R.sup.10--(C.sub.2-C.sub.4)-alkanoylamino R.sup.1 groups are optionally substituted by 1 or 2 substituents independently selected from halo, C.sub.1-C.sub.4 alkyl, cyano, methanesulfonyl and C.sub.1-C.sub.4 alkoxy; or two R.sup.1 groups are taken together with the carbons to which they are attached to form a 5-8 membered ring that includes 1 or 2 heteroatoms selected from O, S and N; R.sup.2 is hydrogen or C.sub.1-C.sub.6 alkyl optionally substituted by 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.4 alkoxy, --NR.sup.6R.sup.6, and --SO.sub.2R.sup.5; n is 1 or 2 and each R.sup.3 is independently selected from hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, --NR.sup.6R.sup.6, and C.sub.1-C.sub.4 alkoxy, wherein the alkyl moieties of said R.sup.3 groups are optionally substituted by 1 to 3 substituents independently selected from halo, C.sub.1-C.sub.4 alkoxy, --NR.sup.6R.sup.6, and --SO.sub.2R; and, R.sup.4 is azido or -(ethynyl)-R.sup.11 wherein R.sup.11 is hydrogen or C.sub.1-C.sub.6 alkyl optionally substituted by hydroxy, --OR.sup.6, or --NR.sup.6R.sup.6. 18. The method of claim 17 wherein the EGFR inhibitor is a compound of formula I selected from the group consisting of: (6,7-dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-4-yl)-[3-(3'-hydroxypropyn-1-yl)phenyl]-amine; [3-(2'-(aminomethyl)-ethynyl)phenyl]-(6,7-dimethoxyquinazolin-4-yl)-amine- ; (3-ethynylphenyl)-(6-nitroquinazolin-4-yl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(4-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-2-methylphenyl)-amine; (6-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(6-methanesulfonylaminoquinazolin-4-yl)-amine; (3-ethynylphenyl)-(6,7-methylenedioxyquinazolin-4-yl)-amine; (6,7-dimethoxyquinazolin-4-yl)-(3-ethynyl-6-methylphenyl)-amine; (3-ethynylphenyl)-(7-nitroquinazolin-4-yl)-amine; (3-ethynylphenyl)-[6-(4'-toluenesulfonylamino)quinazolin-4-yl]-amine; (3-ethynylphenyl)-{6-[2'-phthalimido-eth-1'-yl-sulfonylamino]quinazolin-4- -yl}-amine; (3-ethynylphenyl)-(6-guanidinoquinazolin-4-yl)-amine; (7-aminoquinazolin-4-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(7-methoxyquinazolin-4-yl)-amine; (6-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; (7-carbomethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)-amine; (3-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-azido-5-chlorophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (4-azidophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-ethynylphenyl)-(6-methansulfonyl-quinazolin-4-yl)-amine; (6-ethansulfanyl-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine; (6,7-dimethoxy-quinazolin-4-yl)-[3-(propyn-1'-yl)-phenyl]-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(5-ethynyl-2-methyl-phenyl)-- amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-4-fluoro-ph- enyl)-amine; [6,7-bis-(2-chloro-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; [6-(2-chloro-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phe- nyl)-amine; [6,7-bis-(2-acetoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 2-[4-(3-ethynyl-phenylamino)-7-(2-hydroxy-ethoxy)-quinazolin-6-yloxy]-eth- anol; [6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethyn- yl-phenyl)-amine; [7-(2-chloro-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phe- nyl)-amine; [7-(2-acetoxy-ethoxy)-6-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-ph- enyl)-amine; 2-[4-(3-ethynyl-phenylamino)-6-(2-hydroxy-ethoxy)-quinazolin-7-yloxy]-eth- anol; 2-[4-(3-ethynyl-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yloxy- ]-ethanol; 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-- yloxy]-ethanol; [6-(2-acetoxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-ph- enyl)-amine; (3-ethynyl-phenyl)-{6-(2-methoxy-ethoxy)-7-[2-(4-methyl-piperazin-1-yl)-e- thoxy]-quinazolin-4-yl}-amine; (3-ethynyl-phenyl)-[7-(2-methoxy-ethoxy)-6-(2-morpholin-4-yl)-ethoxy)-qui- nazolin-4-yl]-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-dibutoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-diisopropoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynyl-2-methyl-phenyl)-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynyl-2-methyl-phenyl)-- amine; (3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinaz- olin-1-yl]-amine; [6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; 2-[4-(3-ethynyl-phenylamino)-6-(2-methoxy-ethoxy)-quinazolin-7-yloxy]-eth- anol; (6,7-dipropoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-5-fluoro-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(5-ethynyl-2-methyl-phenyl)-amine; (6,7-diethoxy-quinazolin-4-yl)-(3-ethynyl-4-methyl-phenyl)-amine; (6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine; (6-aminomethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine- ; (6-aminocarbonylethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine- ; (6-aminocarbonylmethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine- ; (6-aminocarbonylethyl-7-ethoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6-aminocarbonylmethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylphenyl)-am- ine; (6-aminocarbonylmethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-a- mine; (6-aminocarbonylmethyl-7-methoxy-quinazolin-4-yl)-(3-ethynylphenyl)-- amine; (6-aminocarbonylethyl-7-isopropoxy-quinazolin-4-yl)-(3-ethynylpheny- l)-amine; and (6-aminocarbonylethyl-7-propoxy-quinazolin-4-yl)-(3-ethynylphenyl)-amine; (6,7-diethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-[6-(2-hydroxy-ethoxy)-7-(2-methoxy-ethoxy)-quinazolin-1- -yl]-amine; [6,7-bis-(2-hydroxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; [6,7-bis-(2-methoxy-ethoxy)-quinazolin-1-yl]-(3-ethynylphenyl)-amine; (6,7-dimethoxyquinazolin-1-yl)-(3-ethynylphenyl)-amine; (3-ethynylphenyl)-(6-methanesulfonylamino-quinazolin-1-yl)-amine; and (6-amino-quinazolin-1-yl)-(3-ethynylphenyl)-amine. 19. The method of claim 17 wherein the EGFR inhibitor of formula I is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. 20. The method of claim 19 wherein the EGFR inhibitor N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine is in HCl salt form. 21. The method of claim 20 wherein the EGFR inhibitor N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine is erlotinib, which is present in a substantially homogeneous crystalline polymorph form that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately 6.26, 12.48, 13.39, 16.96, 20.20, 21.10, 22.98, 24.46, 25.14 and 26.91. 22. The method of claim 1 wherein said EGFR inhibitor is an EGFR antibody. 23. The method of claim 1 wherein said EGFR inhibitor blocks the formation of EGFR-EGFR homodimers but not the formation of EGFR-HER2 heterodimers. 24. The method of claim 1 wherein the EGFR inhibitor blocks the formation of EGFR-EGFR homodimers and EGFR-HER2 heterodimers. 25. The method of claim 24 wherein said EGFR inhibitor is an EGFR antibody. 26. The method of claim 25 wherein said EGFR antibody is cetuximab. 27. The method of claim 1 comprising administering to said human subject an effective amount of pertuzumab and erlotinib. 28. The method of claim 27 wherein said pertuzumab and erlotinib exhibit a synergistic anti-tumor activity. 29. The method of claim 27 wherein said cancer is non-small cell lung cancer (NSCLC). 30. The method of claim 29 wherein said cancer is metastatic NSCLC. 31. The method of claim 30 wherein said cancer is poor-risk stage II or stage III NSCLC. 32. The method of claim 1 comprising administering to said patient an effective amount of pertuzumab and cetuximab. 33. The method of claim 32 wherein said pertuzumab and cetuximab exhibit a synergistic anti-tumor activity. 34. The method of claim 1 wherein said HER2 antibody and said EGFR inhibitor are administered simultaneously. 35. The method of claim 1 wherein said HER2 antibody and said EGFR inhibitor are administered consecutively. 36. The method of claim 1 further comprising treating said patient with at least one chemotherapeutic agents. 37. The method of claim 1 further comprising subjecting said patient to radiation therapy. 38. The method of claim 1 further comprising subjecting said patient to standard of care treatment. 39. A method for the treatment of cancer comprising administering to a human subject, an effective amount of a HER2 antibody which is a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's cancer is not driven solely by EGFR, and the cancer is non-small cell lung cancer (NSCLC) which is refractory to chemotherapy. 40. A method for the treatment of cancer comprising administering to a human subject an effective amount of pertuzumab and erlotinib, wherein the subject's cancer is not driven solely by EGFR, and the cancer is non-small cell lung cancer (NSCLC) which is refractory to chemotherapy. 41. A method for the treatment of EGFR and HER2 expressing lung cancer comprising administering to a human subject, an effective amount of a HER2 antibody which is a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's lung cancer is refractory or responds poorly to an EGFR inhibitor and is refractory to chemotherapy. 42. A method for the treatment of EGFR and HER2 expressing lung cancer comprising administering to a human subject, an effective amount of a HER2 antibody which is a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the subject's lung cancer is refractory or responds poorly to a HER2 antibody and is refractory to chemotherapy. 43. A method of treating metastatic non-small cell lung cancer (NSCLC) in a patient comprising administering pertuzumab and erlotinib to a patient with NSCLC each in amounts effective to treat the NSCLC, wherein the treatment is provided as a second or third line therapy. 44. A method of treating metastatic non-small cell lung cancer (NSCLC) in a patient comprising administering pertuzumab and erlotinib to a patient with NSCLC each in amounts effective to treat the NSCLC, wherein the NSCLC is refractory to chemotherapy. 45. A method for the treatment of non-small cell lung cancer (NSCLC) comprising administering to a human subject with NSCLC expressing EGFR and HER2, an effective amount of a HER2 antibody which is a HER2-dimerization inhibitor and an EGFR inhibitor, wherein the EGFR inhibitor is erlotinib, which is present in a substantially homogeneous crystalline polymorph form that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately 6.26, 12.48, 13.39, 16.96, 20.20, 21.10, 22.98, 24.46, 25.14 and 26.91, and wherein the NSCLC does not show a complete response to treatment with said HER2 antibody or said EGFR inhibitor when administered as a single agent.

Details for Patent 8,163,287

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2025-07-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2025-07-22
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2025-07-22